EGFR and thyroid gland carcinoma: Vemurafenib (BRAFV600E inhibitor) resistance in thyroid cancer can be addressed by combining it with EGFR (Epidermal Growth Factor Receptor) inhibitors (Notarangelo et al., 2017).